AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25064421 — intervention group
Group type: EXPERIMENTAL
Intervention: STAGE‐12 therapy (high exposure, n=158)
Number of subjects: 234
Study 25064421 — intervention group
Group type: COMPARATOR
Intervention: TAU alone (n=76)
Number of subjects: 234
Study 21194910 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2 100,000 units orally at baseline
Number of subjects: 58
Study 21194910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 20003299 — intervention group
Group type: EXPERIMENTAL
Intervention: OSTEOPOROSIS CHOICE
Number of subjects: 0
Study 20003299 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 0
Study 16982815 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow rate of 8 mL/sec
Number of subjects: 40
Study 16982815 — intervention group
Group type: COMPARATOR
Intervention: Flow rate of 4 mL/sec
Number of subjects: 40
Study 16982815 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow rate of 8 mL/sec with individualized scan delay
Number of subjects: 40
Study 16982815 — intervention group
Group type: COMPARATOR
Intervention: Flow rate of 4 mL/sec with fixed scan delay
Number of subjects: 40
Study 14605513 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise (LEX, n=18)
Number of subjects: 43
Study 14605513 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise (HEX, n=15)
Number of subjects: 43
Study 14605513 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 43
Study 11103232 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CDDP and 5-FU with chemo- and radiotherapy
Number of subjects: 0
Study 8882105 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 4% lidocaine with antibiotic drops
Number of subjects: 122
Study 8882105 — intervention group
Group type: COMPARATOR
Intervention: Placebo with antibiotic drops
Number of subjects: 122
Study 1433853 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 31
Study 1433853 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 31
Study 1433853 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 31
Study 4011356 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive program with mock-up demonstration, written handouts, physician's orders for demonstration and discharge in a car seat
Number of subjects: 129
Study 4011356 — intervention group
Group type: COMPARATOR
Intervention: Regular hospital program
Number of subjects: 129
Study 30720530 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on group (11 hours of hands-on massage practice)
Number of subjects: 20
Study 30720530 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on group
Number of subjects: 20
Study 30720530 — intervention group
Group type: COMPARATOR
Intervention: Online-only group
Number of subjects: 20
Study 28745941 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote management care (including online patient portals, e‐mails, follow‐up phone calls, home health devices)
Number of subjects: 77
Study 28745941 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote management care
Number of subjects: 77
Study 27487914 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration + hemophagocytic lymphohistiocytosis-2004 group
Number of subjects: 33
Study 27487914 — intervention group
Group type: COMPARATOR
Intervention: Hemophagocytic lymphohistiocytosis-2004 group
Number of subjects: 33
Study 27487914 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration
Number of subjects: 33
Study 23642962 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin Damage and Severity Index (SDASI)
Number of subjects: 9
Study 23642962 — intervention group
Group type: COMPARATOR
Intervention: Three different grades of infill materials
Number of subjects: 9
Study 22072741 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg zoledronate
Number of subjects: 180
Study 22072741 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg zoledronate
Number of subjects: 180
Study 22072741 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg zoledronate
Number of subjects: 180
Study 22072741 — intervention group
Group type: EXPERIMENTAL
Intervention: zoledronate (all doses)
Number of subjects: 180
Study 22072741 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 180
Study 20487050 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/40 mg
Number of subjects: 786
Study 20487050 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 40 mg
Number of subjects: 786
Study 20487050 — intervention group
Group type: COMPARATOR
Intervention: rosuvastatin 5 or 10 mg
Number of subjects: 786
Study 18579811 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of oral rivaroxaban once daily
Number of subjects: 4541
Study 18579811 — intervention group
Group type: COMPARATOR
Intervention: 40 mg of enoxaparin subcutaneously once daily
Number of subjects: 4541
Study 16049380 — intervention group
Group type: EXPERIMENTAL
Intervention: EASI plus high dose oxytocin
Number of subjects: 151
Study 16049380 — intervention group
Group type: COMPARATOR
Intervention: PGE2 gel
Number of subjects: 151
Study 12444817 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine, 20 to 80 mg/day (N = 30)
Number of subjects: 60
Study 12444817 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 30)
Number of subjects: 60
Study 10638387 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 10 mg/kg thrice daily
Number of subjects: 90
Study 10638387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 10 mg/kg thrice daily
Number of subjects: 90
Study 10638387 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 2.5 mg/kg twice daily for 5 days
Number of subjects: 90
Study 7569731 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (n-3 PUFAs) supplementation, 4 g per day for 6 months
Number of subjects: 601
Study 7569731 — intervention group
Group type: COMPARATOR
Intervention: Control group (no n-3 PUFA supplementation)
Number of subjects: 601
Study 1940932 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg three times daily for 10 days starting on the first postoperative day
Number of subjects: 200
Study 1940932 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic treatment
Number of subjects: 200
Study 6266028 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous calcium heparin, 5000 units (Ul) 2 hours and 30 minutes before surgery then every 12 hours for 15 days (Protocol A)
Number of subjects: 2420
Study 6266028 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous calcium heparin, same dose and duration starting 24 to 72 hours after surgery (Protocol B)
Number of subjects: 2420
Study 6266028 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulant treatment (Protocol O)
Number of subjects: 2420
Study 30863894 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose soy drink (35 mg/day isoflavones) for 12 weeks
Number of subjects: 101
Study 30863894 — intervention group
Group type: COMPARATOR
Intervention: Low dose soy drink (10 mg/day isoflavones) for 12 weeks
Number of subjects: 101
Study 30863894 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose soy drink (60 mg/day isoflavones) for 12 weeks
Number of subjects: 101
Study 29722251 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (IPC-arm)
Number of subjects: 12
Study 29722251 — intervention group
Group type: EXPERIMENTAL
Intervention: Local ischemic preconditioning (IPC-leg)
Number of subjects: 12
Study 29722251 — intervention group
Group type: COMPARATOR
Intervention: SHAM treatment
Number of subjects: 12
Study 29722251 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (IPC)
Number of subjects: 12
Study 29722251 — intervention group
Group type: EXPERIMENTAL
Intervention: Local ischemic preconditioning (IPC)
Number of subjects: 12
Study 28602039 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 0
Study 28602039 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 0
Study 25644485 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART technique (Stapled Mesh stomA Reinforcement Technique)
Number of subjects: 22
Study 25644485 — intervention group
Group type: COMPARATOR
Intervention: Control group (stoma resiting without mesh reinforcement)
Number of subjects: 22
Study 22463392 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic perconditioning during transport to hospital
Number of subjects: 0
Study 21251813 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly docetaxel (n=79)
Number of subjects: 162
Study 21251813 — intervention group
Group type: COMPARATOR
Intervention: 3-weekly docetaxel (n=77)
Number of subjects: 162
Study 19703948 — intervention group
Group type: EXPERIMENTAL
Intervention: Vulnamin gel with elastocompression
Number of subjects: 30
Study 19703948 — intervention group
Group type: COMPARATOR
Intervention: Inert gel vehicle with elastocompression
Number of subjects: 30
Study 17466227 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 2445
Study 17466227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2445
Study 12731679 — intervention group
Group type: EXPERIMENTAL
Intervention: TCU Cognitive Skills Module (CSM)
Number of subjects: 0
Study 12731679 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 10496523 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-gland proliferation (adenomas)
Number of subjects: 67
Study 10496523 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-gland proliferation (primary hyperparathyroidism)
Number of subjects: 67
Study 10496523 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary hyperparathyroidism
Number of subjects: 67
Study 8622022 — intervention group
Group type: EXPERIMENTAL
Intervention: CEF chemotherapy (first-line treatment)
Number of subjects: 326
Study 8622022 — intervention group
Group type: COMPARATOR
Intervention: CMF-based adjuvant chemotherapy
Number of subjects: 326
Study 8622022 — intervention group
Group type: COMPARATOR
Intervention: Anthracycline-based adjuvant chemotherapy
Number of subjects: 326
Study 8622022 — intervention group
Group type: COMPARATOR
Intervention: Not receiving adjuvant chemotherapy
Number of subjects: 326
Study 8622022 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 326
Study 1751940 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate
Number of subjects: 181
Study 1751940 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine decanoate
Number of subjects: 181
Study 7326852 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 micrograms of triiodothyronine (T3) daily
Number of subjects: 20
Study 7326852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31256261 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of furosemide
Number of subjects: 80
Study 31256261 — intervention group
Group type: COMPARATOR
Intervention: Bolus intermittent furosemide
Number of subjects: 80
Study 31256261 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 80
Study 30760421 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 129
Study 30760421 — intervention group
Group type: COMPARATOR
Intervention: Control (no statins)
Number of subjects: 129
Study 28300431 — intervention group
Group type: EXPERIMENTAL
Intervention: Honest response condition
Number of subjects: 243
Study 28300431 — intervention group
Group type: EXPERIMENTAL
Intervention: Faking-good response condition
Number of subjects: 243
Study 28300431 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproduce response condition
Number of subjects: 243
Study 28300431 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructed faking (faking-good)
Number of subjects: 243
Study 28300431 — intervention group
Group type: EXPERIMENTAL
Intervention: Applicants' faking behavior
Number of subjects: 243
Study 28300431 — intervention group
Group type: EXPERIMENTAL
Intervention: General faking behavior
Number of subjects: 243
Study 26215651 — intervention group
Group type: EXPERIMENTAL
Intervention: Living well with Asthma (online self-management resource)
Number of subjects: 10
Study 24046400 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluent containing 0.30 µg of 25(OH)D3
Number of subjects: 61
Study 24046400 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluent containing 0.60 µg of 25(OH)D3
Number of subjects: 61
Study 24046400 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluent containing 1.20 µg of 25(OH)D3
Number of subjects: 61
Study 24046400 — intervention group
Group type: COMPARATOR
Intervention: Noninjected controls
Number of subjects: 61
Study 24046400 — intervention group
Group type: COMPARATOR
Intervention: Diluent-injected controls
Number of subjects: 61
Study 21492164 — intervention group
Group type: EXPERIMENTAL
Intervention: Oltipraz 60 mg bid for 24 weeks
Number of subjects: 83
Study 21492164 — intervention group
Group type: EXPERIMENTAL
Intervention: Oltipraz 90 mg qd for 24 weeks
Number of subjects: 83
Study 21492164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 18646345 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored group educational program including a video and Q&A session with an African American physician
Number of subjects: 430
Study 18646345 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (crossover design)
Number of subjects: 430
Study 16472330 — intervention group
Group type: EXPERIMENTAL
Intervention: rizatriptan 10-mg wafer
Number of subjects: 372
Study 15658651 — intervention group
Group type: EXPERIMENTAL
Intervention: Liuwei Dihuang Pill (LDP) plus conventional therapy (Gliquidone or insulin) for 3 months
Number of subjects: 72
Study 15658651 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Gliquidone or insulin)
Number of subjects: 72
Study 10027034 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lidocaine aerosol (2.5-4.7 mg kg-1)
Number of subjects: 44
Study 10027034 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 44
Study 10027034 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 44
Study 7628183 — intervention group
Group type: EXPERIMENTAL
Intervention: Zifrosilone 10 mg
Number of subjects: 54
Study 7628183 — intervention group
Group type: EXPERIMENTAL
Intervention: Zifrosilone 300 mg
Number of subjects: 54
Study 7628183 — intervention group
Group type: EXPERIMENTAL
Intervention: Zifrosilone doses > or = 200 mg
Number of subjects: 54
Study 7628183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 16296699 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg daily
Number of subjects: 16
Study 16296699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7018557 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg oestriol gel
Number of subjects: 40
Study 7018557 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg PGF2 alpha gel
Number of subjects: 40
Study 7018557 — intervention group
Group type: COMPARATOR
Intervention: gel alone (control)
Number of subjects: 40
Study 31154425 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I
Number of subjects: 885
Study 31154425 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 885
Study 30010353 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension Tamer (TT) guided BAM sessions for 5-, 10-, or 15-min intervals twice daily over 6 months
Number of subjects: 64
Study 27657471 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (5mg thrice daily for 12 weeks)
Number of subjects: 402
Study 27657471 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus nicorandil
Number of subjects: 402
Study 27657471 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy only
Number of subjects: 402
Study 27657471 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 402
Study 24767094 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher volume of whole blood (30 ml/kg; Tx30)
Number of subjects: 160
Study 24767094 — intervention group
Group type: COMPARATOR
Intervention: Standard volume of whole blood (20 ml/kg; Tx20)
Number of subjects: 160
Study 22218843 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (4 mg oral, 12-week treatment)
Number of subjects: 300
Study 22218843 — intervention group
Group type: COMPARATOR
Intervention: Placebo (look-alike, 12-week treatment)
Number of subjects: 300
Study 21055113 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous irrigation with simple drainage (Arm A)
Number of subjects: 74
Study 21055113 — intervention group
Group type: COMPARATOR
Intervention: Simple drainage only (Arm B)
Number of subjects: 74
Study 18318169 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 0
Study 18318169 — intervention group
Group type: EXPERIMENTAL
Intervention: Emoxipin
Number of subjects: 0
Study 18318169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16255449 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life and psychological variables in primary care studies
Number of subjects: 0
Study 16255449 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and physical activity variables
Number of subjects: 0
Study 16255449 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and functional status in residential care for the elderly
Number of subjects: 0
Study 12070194 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine, zileuton, and nedocromil sodium
Number of subjects: 17
Study 12070194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 10188719 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels of coffee intake
Number of subjects: 2403
Study 10188719 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of coffee intake
Number of subjects: 2403
Study 10188719 — intervention group
Group type: COMPARATOR
Intervention: One cup of coffee per day or less
Number of subjects: 2403
Study 10188719 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of water intake
Number of subjects: 2403
Study 7594336 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole (30 mg/day)
Number of subjects: 18
Study 31246258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST)
Number of subjects: 0
Study 31246258 — intervention group
Group type: COMPARATOR
Intervention: Care management control condition
Number of subjects: 0
Study 31144445 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 units/mL (Gla‐300)
Number of subjects: 638
Study 31144445 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 638
Study 31144445 — intervention group
Group type: COMPARATOR
Intervention: Both Gla‐300 and IDeg
Number of subjects: 638
Study 28418213 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (0.25, 0.50, 1.0 or 10 mg/mL)
Number of subjects: 52
Study 28418213 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 52
Study 28418213 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 52
Study 25486090 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8ng/kg LPS
Number of subjects: 60
Study 25486090 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6ng/kg LPS
Number of subjects: 60
Study 25486090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23576050 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium claims (disease risk reduction, function, and nutrient-content claims)
Number of subjects: 506
Study 23576050 — intervention group
Group type: COMPARATOR
Intervention: Taste control claim
Number of subjects: 506
Study 23576050 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension status (hypertensives vs normotensives)
Number of subjects: 506
Study 21595743 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 20 mg/day for 7 days
Number of subjects: 30
Study 21595743 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF (adalimumab, Humira®) 40 mg s.c. single dose
Number of subjects: 30
Study 21595743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19412143 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 48
Study 19412143 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine
Number of subjects: 48
Study 17242700 — intervention group
Group type: EXPERIMENTAL
Intervention: p16(INK4a) negative tumours
Number of subjects: 300
Study 17242700 — intervention group
Group type: EXPERIMENTAL
Intervention: p16(INK4a) positive tumours (intermediate expression)
Number of subjects: 300
Study 17242700 — intervention group
Group type: EXPERIMENTAL
Intervention: High pRb expression
Number of subjects: 300
Study 17242700 — intervention group
Group type: EXPERIMENTAL
Intervention: High pRb expression in optimally debulked patients (n=82)
Number of subjects: 300
Study 15052436 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanically stapled anastomoses
Number of subjects: 187
Study 15052436 — intervention group
Group type: COMPARATOR
Intervention: Hand-sutured anastomoses
Number of subjects: 187
Study 11679026 — intervention group
Group type: EXPERIMENTAL
Intervention: Passiflora extract 45 drops/day plus placebo tablet
Number of subjects: 36
Study 11679026 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam 30 mg/day plus placebo drops
Number of subjects: 36
Study 9456071 — intervention group
Group type: EXPERIMENTAL
Intervention: Active substance provocation
Number of subjects: 0
Study 9456071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7889022 — intervention group
Group type: COMPARATOR
Intervention: Haldol Decanoas (reference product)
Number of subjects: 15
Study 7889022 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable haloperidol decanoate 141 mg/ml (test product)
Number of subjects: 15
Study 3251495 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 8
Study 3251495 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 8
Study 30544411 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 4 mg (group O)
Number of subjects: 46